Abstract
One method of determining potentially useful antipsychotic dosing ranges is to examine what is being used in the field. Once a medication has become available for some time and clinicians are experienced in using it, a possible assumption is that the doses used in the “real world” may be the best ones to try. For patients with a suboptimal treatment response, a place to look for dosing information would be among inpatients with persistent symptoms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol. 2005;25:388-391.
Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry. 2005;66:1512-1516.
Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry. 2009;70:975-982.
Citrome L, Jaffe A, Levine J. Datapoints: The ups and downs of dosing second-generation antipsychotics. Psychiatr Serv. 2007;58:11.
Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280-291.
Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new secondgeneration antipsychotics. Postgrad Med. 2011;123:153-162.
Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Expert Rev Neurother. 2009;9:1045-1058.
Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255-262.
Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392-400.
Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2011;31:160-168.
Honer WG, MacEwan GW, Gendron A, et al; STACK Study Group. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:13-20.
Goff D, McEvoy J, Citrome L, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. In press.
Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: part 1. J Psychiatr Pract. 2012;18:199-204.
Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: part 2. Metabolism and elimination. J Psychiatr Pract. 2012;18:361-368.
Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer “atypical” antipsychotics: part 3. Effects of renal and hepatic impairment. J Psychiatr Pract. 2012;18:430-437
Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29:815-825.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Healthcare
About this chapter
Cite this chapter
Citrome, L. (2013). Dosing of Antipsychotics: What Evidence Do We Use?. In: Handbook of Treatment-resistant Schizophrenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-88-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-908517-88-3_4
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-86-9
Online ISBN: 978-1-908517-88-3
eBook Packages: MedicineMedicine (R0)